Aclarion, Inc. (ACON) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Aclarion, Inc. is a healthcare technology company leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments via its Nociscan reports. The company is classified as an emerging growth company and a smaller reporting company. During the period, the company executed two reverse stock splits (1:335 in January and 1:27 in March 2025), which have been retrospectively applied to all share data.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $19,319 | $10,971 | $38,309 | $21,085 |
| Gross Profit | $5,140 | $(12,323) | $651 | $(21,685) |
| Net Loss | $(1,600,757) | $(1,238,077) | $(3,638,193) | $(3,637,180) |
| Operating Cash Flow | N/A | N/A | $(4,376,394) | $(3,293,096) |
| Cash & Equivalents (End of Period) | $12,825,657 (as of June 30, 2025) | |||
| Total Liabilities | $564,422 (as of June 30, 2025) |
Liquidity: As of June 30, 2025, the company held approximately $12.8 million in cash and cash equivalents, a significant increase from $453,661 at year-end 2024. Management believes current cash resources will fund operations into the third quarter of 2026.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 76% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 82% year-to-date, driven by increased volume of Nociscan reports in the UK market following local coverage decisions.
- Operating Expenses: Total operating expenses rose 55% in Q2 and 35% YTD. Increases were driven by:
- Sales & Marketing: Higher costs due to the initiation of the "Clarity" clinical trial and travel for UK market support.
- General & Administrative: Significant accruals for the 2025 bonus program (~$199k in Q2) and increased D&O insurance costs.
- Debt Elimination: The company retired all unsecured non-convertible notes in 2024. Consequently, interest expense dropped to zero in 2025 compared to significant expenses in 2024.
- One-Time Settlement: In March 2025, the company paid $687,500 to settle a dispute regarding an investment banking "fee tail" provision, recorded as a penalty/settlement expense.
Guidance, Outlook, and Risks
- Capital Raising: During the first six months of 2025, the company raised approximately $20.1 million in gross proceeds through a public offering of units, two registered direct offerings, and warrant exercises.
- Outlook: Management expects current cash to fund operations into Q3 2026 but notes that additional funding will be required for continued technology development and commercialization.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses related to limited segregation of duties and a lack of adequate accounting resources for complex transactions. Remediation efforts are ongoing.
- Stockholder Action: In July 2025, stockholders approved a proposed reverse stock split but rejected an amendment to the 2022 Equity Incentive Plan.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the stated projection of funding through Q3 2026, given the high operating expenses relative to revenue.
- Revenue Concentration: Confirm the sustainability of the UK market growth driving the 76% revenue increase and the status of reimbursement coverage.
- Internal Control Remediation: Review the timeline and progress of fixing the material weaknesses in internal controls over financial reporting.
- Dilution Impact: Assess the impact of the recent cashless exercise of Series B warrants (approx. 14.7 million shares issued) on existing shareholder ownership.
- Legal Settlements: Monitor for any further legal disputes or penalties similar to the $687,500 investment banking settlement paid in Q1 2025.